Loading...
Market
Market position of Asahi Kasei's pharma sector by end of 2025
4
Asahi Kasei•Swedish•Calliditas Therapeutics•American Depositary Share•ADS•Calliditas•Tarpeyo•SofinnovaVC•Amolyt Pharma•CLI LimFlow
Resolution / Starting Odds
Top 10 globally • 25%
Top 50 globally • 25%
No significant change • 25%
Loses market position • 25%
Market analysis reports and industry rankings
Story
Asahi Kasei to Acquire Calliditas Therapeutics for $1.1 Billion in SEK 416 per ADS Deal
May 28, 2024, 09:19 AM
Japanese conglomerate Asahi Kasei has announced its intention to acquire Swedish drugmaker Calliditas Therapeutics for approximately $1.1 billion. The deal, which includes an offer of SEK 416 or about USD $39.37 in cash per American Depositary Share (ADS), aims to bolster Asahi Kasei's pharmaceutical business. Calliditas, known for its IgA nephropathy therapy Tarpeyo, will be acquired for $1.05 billion in cash. The acquisition price is also noted as SEK 208 per share or 1.2 billion dollars. This acquisition marks the third successful exit for SofinnovaVC in the last six months, following the exits of Amolyt Pharma and CLI LimFlow.
View original story
Similar markets
Leader in biotech market • 25%
Top 5 in biotech market • 25%
Moderately successful • 25%
Struggles to scale • 25%
Stock price up more than 10% • 25%
Stock price up 5-10% • 25%
Stock price unchanged or down • 25%
Stock price down more than 5% • 25%
Significant increase in investment • 33%
Moderate increase • 33%
No significant change • 34%
Market position strengthened • 33%
Market position weakened • 33%
Market position remains stable • 34%
Biocon's biosimilar dominates • 33%
Biogen's biosimilar dominates • 33%
Equal market share between Biocon and Biogen • 34%
Below 20% market share • 33%
20-40% market share • 34%
Above 40% market share • 33%
Increases • 33%
Decreases • 33%
Remains the same • 33%
Decrease by more than 10% • 25%
Decrease by less than 10% • 25%
Remain stable • 25%
Increase • 25%
Increase • 33%
No significant change • 33%
Decrease • 33%
Eylea retains majority market share • 50%
Biosimilars gain majority market share • 50%